Patrick Michael Round
Chief Tech/Sci/R&D Officer at NewAmsterdam Pharma BV
Profile
Patrick Michael Round is the founder of ario pharma Ltd.
He currently holds three positions, including Director at Xention Ltd., Venture Partner at Forbion Capital Partners Management Holding BV, and Chief Medical Officer at NewAmsterdam Pharma BV.
Previously, he held positions such as Director of Clinical Development at Glaxo Wellcome Plc, Development Director at Celltech R&D, Inc., Senior Vice President at MedImmune Ltd., Principal at Novo Nordisk A, and Chief Medical Officer at Xention Pharma Ltd.
He also served as Principal at the Faculty of Pharmaceutical Medicine.
Dr. Round received his undergraduate degree from the University of London in 1982.
Patrick Michael Round active positions
Companies | Position | Start |
---|---|---|
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Chief Tech/Sci/R&D Officer | - |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Director/Board Member | 2016-05-16 |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 2017-12-31 |
Former positions of Patrick Michael Round
Companies | Position | End |
---|---|---|
ario pharma Ltd.
ario pharma Ltd. Pharmaceuticals: MajorHealth Technology ario pharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of respiratory indications. The company was founded by John Ford and Patrick M. Round in 2010 and is headquartered in Great Shelford, the United Kingdom. | Founder | - |
Glaxo Wellcome Plc | Chief Tech/Sci/R&D Officer | 2011-06-27 |
Celltech R&D, Inc.
Celltech R&D, Inc. Drugstore ChainsRetail Trade Celltech R&D, Inc. provides research and development services for pharmaceutical products. The private company is based in Bothell, WA. | Corporate Officer/Principal | - |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Chief Tech/Sci/R&D Officer | - |
Faculty of Pharmaceutical Medicine | Corporate Officer/Principal | - |
Training of Patrick Michael Round
University of London | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
NOVO NORDISK A/S | Health Technology |
Private companies | 9 |
---|---|
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Faculty of Pharmaceutical Medicine | |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Health Technology |
Celltech R&D, Inc.
Celltech R&D, Inc. Drugstore ChainsRetail Trade Celltech R&D, Inc. provides research and development services for pharmaceutical products. The private company is based in Bothell, WA. | Retail Trade |
ario pharma Ltd.
ario pharma Ltd. Pharmaceuticals: MajorHealth Technology ario pharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of respiratory indications. The company was founded by John Ford and Patrick M. Round in 2010 and is headquartered in Great Shelford, the United Kingdom. | Health Technology |
Glaxo Wellcome Plc | Health Technology |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Health Technology |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
- Stock Market
- Insiders
- Patrick Michael Round